Intradermal Vaccination of Adults with Three Low Doses (2 μg) of Recombinant Hepatitis B Vaccine. II. Persistence of Immunity and Induction of Immunologic Memory
Of the 110 dentists who had presented seroconversion 50 days after the intradermal application of three 2 μg doses of the Belgian recombinant vaccine against hepatitis B (HB), administered eight years before at an interval of one month between the 1st and 2nd doses and of five months between the 2nd...
Gespeichert in:
Veröffentlicht in: | Memórias do Instituto Oswaldo Cruz 2004-02, Vol.98 (8) |
---|---|
Hauptverfasser: | , , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
Zusammenfassung: | Of the 110 dentists who had presented seroconversion 50 days after the
intradermal application of three 2 μg doses of the Belgian
recombinant vaccine against hepatitis B (HB), administered eight years
before at an interval of one month between the 1st and 2nd doses and of
five months between the 2nd and 3rd doses, 51 were included for the
assessment of the persistence of immunity. None of the dentists had
hepatitis or had received HB vaccine during this period. All subjects
were submitted to serological tests for the detection of the following
markers of hepatitis B virus (HBV) infection: HBsAg, anti-HBc, HBeAg,
anti-HBe, and anti-HBs, with no HBsAg, anti-HBc, HBeAg or anti-HBe
being detected. A microparticle enzyme immunoassay (MEIA) revealed the
presence of anti-HBs at protective titers (≥ 10 mIU/ml) in 42
dentists (82.4%), with the anti-HBs titer being higher than 100 mIU/ml
in 36 of them (70.6%) (good responders), between 10 and 100 mIU/ml in 6
(11.8%) (poor responders), and lower than 10 mIU/ml in 9 (17.6%)
(non-responders). According to clinical data and serological tests,
none of the dentists had presented disease or latent HBV infection
during the eight years following the first vaccination. A 2 μg
booster dose was administered intradermally to eight dentists with
anti-HBs titers lower than 10 mIU/ml (non-responders) and to six
dentists with titers ranging from 10 to 100 mIU/ml (poor responders);
the determination of anti-HBs one month later demonstrated the
occurrence of seroconversion in the eight non-responders and an
increase in anti-HBs titer in the six poor responders. In summary, the
present results demonstrated the prolonged persistence of protection
against HBV infection and the development of immunologic memory
provided by vaccination against HB - with intra-dermal application of
three 2 μg doses of the Belgian recombinant vaccine at 0, 1, and 6
months - carried out eight years before in 51 dentists. |
---|---|
ISSN: | 1678-8060 |